Physician profile
Jessica Marie Goettl
NPI 1548632722
$58,540.67
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,569 · 2022: $17K · 2023: $18K · 2024: $7,901 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,030.00 |
| Food and Beverage | $2,425.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $51,860.49 | 2021-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $1,645.33 | 2021-2025 | Corevalve Evolut R, Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $982.22 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $585.31 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.11 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $417.28 | 2021-2023 | Mounjaro, Jardiance, Lyumjev |
| Amarin Pharma, INC. | $287.14 | 2021-2023 | |
| Esperion Therapeutics, INC. | $280.83 | 2021-2025 | Nexletol |
| Abbvie INC. | $276.77 | 2021-2025 | |
| Amgen INC. | $224.11 | 2021-2024 | Tepezza, Repatha |
| Astrazeneca Pharmaceuticals Lp | $216.77 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $204.93 | 2021-2024 | |
| Dexcom, INC. | $164.81 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $151.69 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $126.37 | 2021-2023 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $118.58 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $99.49 | 2021-2023 | Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $62.37 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $52.30 | 2021-2024 | Unithroid |
| Pfizer INC. | $51.36 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.20 | 2021 | |
| Radius Health, INC. | $31.75 | 2022 | |
| Clarus Therapeutics INC. | $29.05 | 2021 | |
| Halozyme INC | $26.57 | 2023 | |
| Antares Pharma, INC. | $21.54 | 2025 | Xyosted |
| Recordati_rare_diseases_inc. | $21.37 | 2022 | |
| Eusa Pharma (US) LLC | $21.37 | 2022 | |
| Corcept Therapeutics | $21.02 | 2023 | Korlym |
| Zealand Pharma US, INC. | $20.89 | 2022 | |
| Cequr Corporation | $20.03 | 2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $19.85 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.12 | 2021 | |
| Ibsa Pharma INC. | $12.08 | 2022 | |
| Medicure Pharma INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Goettl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.